Drug General Information (ID: DDITB1OVJP)
  Drug Name Tolvaptan Drug Info Potassium bicarbonate Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Vasopressin Antagonists Minerals And Electrolytes
  Structure

 Mechanism of Tolvaptan-Potassium bicarbonate Interaction (Severity Level: Moderate)
     Increased risk of hyperkalemia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Tolvaptan Potassium bicarbonate
      Mechanism Hyperkalemia Hyperkalemia
      Key Mechanism Factor 1
Factor Name Hyperkalemia
Factor Description Hyperkalemia is a condition in which the level of potassium in the blood is higher than normal. While mild cases may not produce symptoms, severe hyperkalemia can lead to fatal arrhythmias if left untreated.
      Mechanism Description
  • Increased risk of hyperkalemia by the combination of Tolvaptan and Potassium bicarbonate 

Recommended Action
      Management Serum potassium levels should be checked regularly during concomitant therapy with tolvaptan and other agents that can increase serum potassium such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, and miscellaneous agents like cyclosporin, heparin, tacrolimus, and trimethoprim. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.

References
1 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.